07:00 , Apr 23, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Antibody-based protease inhibitors

Drug platforms TECHNOLOGY: Antibody scaffolds In vitro studies suggest insertion of disulfide-bridged peptide inhibitors of serine proteases into antibody CDR3 domains could generate protease inhibitors with high target affinity and specificity. The CDR3H loop of...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Clinical News

Elafin: Phase II data

The investigator-led, double-blind, U.K. Phase II EMPIRE trial in 87 patients undergoing coronary artery bypass graft (CABG) surgery showed that a single pre-operative dose of Elafin did not significantly reduce plasma troponin I AUC from...
07:00 , May 26, 2014 |  BC Week In Review  |  Company News

Proteo, Biotech Development Corp. deal

Financing company Biotech Development will provide up to €3.5 million ($4.8 million) in funding to support development of Proteo's Elafin tiprelestat in the EU to prevent acute postoperative inflammatory complications after resection of esophageal cancer....
08:00 , Nov 18, 2013 |  BC Week In Review  |  Clinical News

Elafin: Completed Phase II enrollment

Proteo completed enrollment of 87 patients who are undergoing coronary bypass surgery in the double-blind, placebo-controlled, U.K. Phase II EMPIRE trial evaluating intraoperative Elafin. Proteo also said it completed a sub-study in which 10 healthy...
07:00 , Apr 1, 2013 |  BC Week In Review  |  Clinical News

Elafin regulatory update

Proteo said FDA granted Orphan Drug designation for Elafin to prevent inflammatory complications of transthoracic esophagectomy, a surgical procedure for esophageal cancer. Elafin has completed Phase II testing for the indication and has Orphan Drug...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Elafin regulatory update

Proteo said FDA granted Orphan Drug designation to Elafin for the treatment of pulmonary arterial hypertension (PAH). Elafin is in preclinical testing for the indication. The natural antagonist of elastase and proteinase-3 is also in...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Elafin: Phase II ongoing

Proteo said it has enrolled 75% of the planned 80 patients who are undergoing coronary bypass surgery in the double-blind, placebo-controlled, U.K. Phase II EMPIRE trial evaluating intraoperative Elafin. Proteo also said it received approval...
08:00 , Nov 8, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Elafin-secreting lactic acid bacteria for treating inflammatory bowel disease (IBD) Elafin-secreting lactic acid bacteria could be useful for treating IBD. Two food-grade strains of lactic...
08:00 , Nov 8, 2012 |  BC Innovations  |  Tools & Techniques

IBD's bacteria cafeteria

The challenges of delivering the protease inhibitor elafin to the gut have stymied efforts to use this anti-inflammatory protein as a therapeutic for intestinal inflammation. Now, researchers in France have engineered food-grade lactic acid bacteria...
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Proteo, Minapharm preclinical data

Researchers at Stanford University and colleagues reported data from neonatal mice genetically modified to express Elafin in their vascular endothelium showing that the mice were almost completely protected against mechanical ventilator-induced lung inflammation. Specifically, Elafin-expressing...